$11.20
+5.79 (+107.02%)
Open$11.38
Previous Close$5.41
Day High$12.50
Day Low$9.43
52W High$13.90
52W Low$1.50
Volume—
Avg Volume11.55M
Market Cap1.01B
P/E Ratio—
EPS$-3.39
SectorBiotechnology
Analyst Ratings
Buy
14 analysts
Price Target
+217.4% upside
Current
$11.20
$11.20
Target
$35.55
$35.55
$27.68
$35.55 avg
$47.36
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 90.24M | 87.45M | 85.26M |
| Net Income | -25,675,790 | -26,182,971 | -21,946,443 |
| Profit Margin | -28.5% | -29.9% | -25.7% |
| EBITDA | -28,181,466 | -22,488,865 | -22,555,214 |
| Free Cash Flow | -17,519,035 | -21,453,021 | -16,827,154 |
| Rev Growth | -3.7% | +3.8% | +9.6% |
| Debt/Equity | 1.03 | 0.84 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |